nach oben

Medical Oncology

Erschienen in:

01.03.2011 | Original paper

Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors

verfasst von: Majid Kheirollahi, Masoud Mehr-Azin, Naser Kamalian, Parvin Mehdipour

Erschienen in: Medical Oncology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Cyclin D2, P53, Rb and ATM as cell cycle genes regulate cell growth and proliferation. Considering their roles, we assumed that they have different level of mRNA expression in different grades of brain tumors. To determine this point, we investigated the mRNA expression in two types of brain tumors, including astrocytoma and meningioma. The mRNA of 52 brain tumor samples were extracted; cyclin D2, P53, Rb and ATM mRNA expression was quantified using the real-time quantitative reverse-transcription polymerase chain reaction. We compared mRNA expression of these genes between astrocytoma and meningioma tumors and also between different grades of them. Cyclin D2, P53, Rb and ATM had higher expression in astrocytoma than meningioma tumors. Higher grade (III and IV) of astrocytoma tumors had up-regulation for cyclin D2 and ATM genes, but higher grades of these tumors showed down-regulation of P53 and Rb genes. Analysis of relative expression between two grades of meningioma tumors showed a high down-regulation in grade II related to grade I. Also, cyclin D2, P53, Rb and ATM mRNA expression in each group of tumors (meningioma and astrocytoma) showed a highly positive correlation in lower grades. Considering this fact and also different templates of up- and down-regulation for these genes’ interaction in different types of brain tumors, it seems that these genes do not have a unique model of interaction.

Neufeld TP, Edgar BA. Connections between growth and the cell cycle. Curr Opin Cell Biol. 1998;10(6):784–90.PubMedCrossRef

Sherr CJ. Mammalian G1 cyclins. Cell. 1993;73(6):1059–65.PubMedCrossRef

Pines J. Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem Sci. 1993;18(6):195–7.PubMedCrossRef

Morgan DO. Principles of CDK regulation. Nature. 1995;374(66518):131–4.PubMedCrossRef

Milde-Langosch K, Hagen M, Bamberger A-M, Löning T. Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol. 2003;122:168–74.CrossRef

Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501–12.PubMedCrossRef

Ekholm SV, Reed SI. Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000;12:676–84.PubMedCrossRef

Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 2001;61(6):2782–7.PubMed

Dey A, She H, Kim L, Boruch A, Guris DL, Carlberg K, et al. Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression. Mol Biol Cell. 2000;11:3835–48.PubMed

10.

Lee WH, Hollingsworth RE, Qian YW, Chen PL, Hong F. RB protein as a cellular ‘‘corral’’ for growth-promoting proteins. Cold Spring Harbor Symp Quant Biol. 1991;56:211–7.PubMed

11.

Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323–30.PubMedCrossRef

12.

Nevins JR, Leone G, Degregori J, Jakoi L. Role of the Rb/E2F pathway in cell growth control. J Cell Physiol. 1997;173:233–6.PubMedCrossRef

13.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.PubMedCrossRef

14.

Lane DP. P53, guardian of the genome. Nature. 1992;358:15–6.PubMedCrossRef

15.

Pietenpol JA, Vogelstein B. Tumor suppressor genes. No room at the p53 inn. Nature. 1993;365:17–8.PubMedCrossRef

16.

Bardeesy N, Beckwith JB, Pelletier J. Clonal expansion and attenuated apoptosis in Wilms’ tumors are associated with p53 gene mutations. Cancer Res. 1995;55(2):215–9.PubMed

17.

Ginsberg K, Mechta F, Yaniv M. Wild type p53 can down-modulate the activity of various promotors. Proc Natl Acad Sci USA. 1991;88:9979–83.PubMedCrossRef

18.

Mack DH, Vartikar J, Pipas JM. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature. 1993;363:281–3.PubMedCrossRef

19.

Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–31.PubMedCrossRef

20.

Deb S, Jackson CT, Subler MA. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol. 1992;66:6164–70.PubMed

21.

Vogelstein B, Kinzler K. p53 function and dysfunction. Cell. 1992;70:523–6.PubMedCrossRef

22.

Ko LJ, Prives C. P53: puzzle and paradigm. Genes Dev. 1996;10:1054–72.PubMedCrossRef

23.

Baross A, Schertzer M, Zuyderduyn SD, Jones SJM, Marra MA, Lansdorp PM. Effect of TERT and ATM on gene expression profiles in human fibroblasts. Genes Chromosomes Cancer. 2004;39:298–310.PubMedCrossRef

24.

Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization. Cell Cycle. 2005;4(9):1166–70.PubMedCrossRef

25.

Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004;23:1547–56.PubMedCrossRef

26.

Pereg Y, Shkedy D, Graaf Pd, Meulmeester E, Edelson-Averbukh M, Salek M, et al. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci USA. 2005;102:5056–61.PubMedCrossRef

27.

Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev. 2001;15:1067–77.PubMedCrossRef

28.

Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat Res. 2005;569:123–32.PubMed

29.

Szabo CI, Schutte M, Broeks A. Are ATM mutations 7271T->G and IVS10–6T->G really high-risk breast cancer susceptibility alleles? Cancer Res. 2004;64:840–3.PubMedCrossRef

30.

Hall J. The ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants. Cancer Lett. 2005;227(2):105–14.PubMedCrossRef

31.

Gutierrez-Enriquez S, Fernet M, Dork T. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer. 2004;40:109–19.PubMedCrossRef

32.

Waha A, Sturne C, Kessler A. Expression of the ATM gene is significantly reduced in sporadic breast carcinomas. Int J Cancer. 1998;78:306–9.PubMedCrossRef

33.

Kovalev S, Mateen A, Zaika AI, O’Hea BJ, Moll UM. Lack of defective expression of the ATM gene in sporadic breast cancer tissues and cell lines. Int J Oncol. 2000;16:825–31.PubMed

34.

Raptis S, Bapat B. Genetic instability in human tumors. EXS. 2006;96:303–20.PubMed

35.

Shiloh Y, Kastan MB. ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res. 2001;83:209–54.PubMedCrossRef

36.

Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med. 2003;3:589–96.PubMedCrossRef

37.

Lichtenstein A, Lichtenstein M, Lichtenstein D, Deborah, Lichtenstein E. http://voicesagainstbraincancer.org/Initiatives/RaiseYourVoiceProgram/2WhatisCancer/tabid/85/Default.aspx. 2009 March 26, 2009 [cited 2009 June 02].

38.

Tatter SB, Wilson CB, Harsh GRIV. Neuroepithelial tumors of the adult brain. 4th ed. Philadelphia: W.B. Saunders; 1995.

39.

Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3(3):255–68.PubMedCrossRef

40.

Lukas J, Bartkova J, Welcker M, Petersen OW, Peters G, Strauss M, et al. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene. 1995;10:2125–34.PubMed

41.

Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene. 1997;14(11):1329–40.PubMedCrossRef

42.

Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature (Lond). 1996;384:470–4.CrossRef

43.

Yu J, Leung WK, Ng EK, To KF, Ebert MP, Go MY, et al. Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Aliment Pharmacol Ther. 2001;15(9):1505–11.CrossRef

44.

Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol. 1999;189:194–200.PubMedCrossRef

45.

Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993;8:2127–33.PubMed

46.

Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene. 1994;9:2663–74.PubMed

47.

Schmidt BA, Rose A, Steinhoff C, Strohmeyer T, Hartmann M, Ackermann R. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Cancer Res. 2001;61:4214–21.PubMed

48.

Diccianni MB, Omura-Minamiawa M, Batova A, Le T, Bridgeman L, Yu AL. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neurobalastoma. Int J Cancer. 1999;80:145–54.PubMedCrossRef

49.

Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995;55:6161–5.PubMed

50.

Hollstein M, Sidransky D, Vogelstein B. p53 mutation in human cancers. Science. 1991;253:49–53.PubMedCrossRef

51.

Quinlan DC, Davidson AS, Summers CL. Accumulation of p53 correlates with a poor prognosis in human lung cancers. Cancer Res. 1992;53:4828–31.

52.

Fontanini G, Boldrini S, Vignati S. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung cancer. Eur J Cancer. 1998;34:718–23.PubMedCrossRef

53.

Maeda T, Matsumura S, Hiranuma H. Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status. J Clin Pathol. 1998;51:771–5.PubMedCrossRef

54.

Ambs S, Bennett WP, Merriam WG. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer. 1998;78(2):233–9.PubMedCrossRef

55.

Ye S, Zhong X, Chen Y. p53 and vascular endothelial growth factor expression in astrocytoma and their relation to angiogenesis. Zhonghua Zhong Liu Za Zhi. 2001;23(4):326–9.PubMed

56.

Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery. 1995;37(2):246–54.PubMedCrossRef

57.

Malmer BS, Feychting M, Lönn S, Lindström S, nberg HG, Ahlbom A, et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 2007;82:229–37.PubMedCrossRef

58.

Mehdipour P, Habibi L, Mohammadi-Asl J, Kamalian N, Azin MM. Three-hit hypothesis in astrocytoma: tracing the polymorphism D1853N in ATM gene through a pedigree of the proband affected with primary brain tumor. J Cancer Res Clin Oncol. 2008;134:1173–80.PubMedCrossRef

Titel: Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors
verfasst von: Majid Kheirollahi
Masoud Mehr-Azin
Naser Kamalian
Parvin Mehdipour
Publikationsdatum: 01.03.2011
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-009-9412-8

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

CYP2E1 Rsa I/Pst I polymorphism and esophageal cancer risk: a meta-analysis based on 1,088 cases and 2,238 controls

Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review

Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia

Renal disorder preceding multiple myeloma

Clear cell adenocarcinoma of the uterine cervix in a young pregnant woman: a case report with immunohistochemical study

Osteolytic lesions marker in multiple myeloma

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie